吉西他滨联合顺铂治疗晚期非小细胞肺癌临床观察

Clinical study of gemcitabine plus cisplatin combined with in the treatment of advanced non-SmaU cell lung cancer

目的评估青西他滨联合顺铂治疗晚期非小细胞肺癌（NSCLC）的近期疗效和安全性。方法对35例晚期NSC∽患者采用吉西他滨1000me,／m2，静滴，第1、8天；顺铂25mg／m2，静滴，第1—3天。28d为1个周期，2个周期后进行一次疗效评价。结果35例患者中完全缓解（CR）0例，部分缓解（PR）14例，稳定（sD）16例，进展（PD）5例，总有效率（cR＋PR）为40．0％。初治组有效率为52．2％，显著高于复治组的116．7％（P〈0．05）。中位疾病进展时间（个rP）6个月。主要毒副作用是骨髓抑制和胃肠道反应。结论GP方案对晚期NSCLC疗效较好，毒副反应轻，是晚期NSCLC特别是初治者的有效治疗方案。

Objective To investigate the efficacy and toxicities of gemcitabine and cisplatin as a chemother- apy regimen for patients with advancd non-small cell lung cancer （NSCLC）. Methods Thirty-five patients with NSCLC were enrolled in this study. Gemclitabine was given on day 1 and 8 at a dose of 1000 mg/m2 and cisplatin at a dose of 25 mg,/m2 on day 1 to 3, The chemotherapy was repeated ever）, 28 days, after 2 cycles for evaluating response. Results Complete response （CR） ,partial ~sponse （PR）,stable disease （SD） and progressive disease （PD） were observed in 0,14,16 and 5 cases,respectiYely,with a response rate （RR） of 40. 0%. The RR in initial treatment group was found more than that inthe retreatment group （ 52, 2% vs 16.7%, P 〈 0. 05 ）. The main toxicities were tol- erable,which inclvded myelosupp ession^nausea, vomiting, and liver damage. Conclusion Gemcitabine combined with cisplatin is effective and safe in the treatment of NSCLC ,especlally in the initial treatment patients.